BLUE BIOFUELS, INC. - FORM 10-Q

Attached files

file	filename
EX-32.1 - BLUE BIOFUELS, INC.	ex32-1.htm
EX-31.2 - BLUE BIOFUELS, INC.	ex31-2.htm
EX-31.1 - BLUE BIOFUELS, INC.	ex31-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the Quarter ended June 30, 2017

Commission File Number: 000-54942

ALLIANCE BIOENERGY PLUS, INC.

(Exact name of registrant as specified in its charter)

Nevada		45-4944960
(State of organization)		(I.R.S. Employer Identification No.)

400 N Congress Avenue Suite 130

West Palm Beach, FL 33401

(Address of principal executive offices)

(888) 607-3555

Registrant’s telephone number, including area code

Former address if changed since last report

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. [ ] Yes [X] No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. [ ] Yes [X] No

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 and Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [X] Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer [ ]	Accelerated Filer [ ]	Non-Accelerated Filer [ ]	Smaller Reporting Company [X]
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [ X]

Securities registered under Section 12(g) of the Exchange Act:

Common Stock $.001 par value

There were 77,631,226 shares of common stock outstanding as of August 11, 2017

TABLE OF CONTENTS

		Page
PART I – FINANCIAL INFORMATION

ITEM 1.	INTERIM FINANCIAL STATEMENTS	3
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION	17
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	22
ITEM 4.	CONTROLS AND PROCEDURES	22

PART II – OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS	24
ITEM 1A.	RISK FACTORS	25
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES	25
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	26
ITEM 4.	MINE SAFETY DISCLOSURES	26
ITEM 5.	OTHER INFORMATION	26
ITEM 6.	EXHIBITS	26

SIGNATURES		27

PART I – FINANCIAL INFORMATION

ITEM 1. INTERIM FINANCIAL STATEMENTS

Alliance BioEnergy Plus, Inc.

CONSOLIDATED BALANCE SHEETS

(Unaudited)

	June 30, 2017			December 31, 2016
ASSETS
Current assets
Cash and cash equivalents	$	354,370		$	49,680
Prepaid expenses		765,353			680,813
TOTAL CURRENT ASSETS		1,119,723			730,493
PROPERTY AND EQUIPMENT, AT COST, NET OF ACCUMULATED DEPRECIATION OF $171,509 AND $133,771 AT JUNE 30, 2017 AND DECEMBER 31, 2016, RESPECTIVELY		225,023			254,761
Other assets
Security deposits		16,305			16,305
Capitalized costs		260,497			260,497
Investment in and advances to an unconsolidated affiliate		7,778,927			7,756,989
TOTAL OTHER ASSETS		8,055,729			8,033,791
TOTAL ASSETS	$	9,400,475		$	9,019,045

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued liabilities	$	609,524		$	341,688
Short term note payable – Related party		2,073,126			2,073,126
Short term note payable – Other		96,570			96,570
Convertible debentures payable – Other, net of discount of $82,213 & $73,334		1,030,700			88,329
Interest payable – Related party		130,259			68,929
Interest payable – Other		101,147			58,350
Derivative liabilities		310,000			914,000
Current liabilities of discontinued operations		36,148			36,148
TOTAL CURRENT LIABILITIES		4,387,474			3,677,140
TOTAL LIABILITIES	$	4,387,474		$	3,677,140

STOCKHOLDER’S EQUITY
Preferred stock; $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding		-			-
Common stock; $0.001 par value; 500,000,000 shares authorized; 77,284,049 shares issued and outstanding at June 30, 2017 and 71,707,493 shares issued and outstanding at December 31, 2016		77,284			71,707
Stock subscription receivable		(5,000	)		(75,000	)
Additional paid-in capital		32,900,588			31,167,713
Accumulated deficit		(27,959,871	)		(25,822,515	)
Total stockholder’s equity		5,013,001			5,341,905
TOTAL EQUITY	$	5,013,001		$	5,341,905

TOTAL LIABILITIES AND STOCKHOLDER’S EQUITY	$	9,400,475		$	9,019,045

See accompanying notes to financial statements

Alliance BioEnergy Plus, Inc.

CONSOLIDATED STATEMENT OF OPERATIONS

(Unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2017			2016			2017			2016
Revenues	$	-		$	-		$	-		$	-

Operating expenses:
General and administrative		1,061,849			1,461,881			1,876,030			2,743,504
Total operating expenses		1,061,849			1,461,881			1,876,030			2,743,504

Loss from operations:		(1,061,849	)		(1,461,881	)		(1,876,030	)		(2,743,504	)

Other (income) expense:
Equity loss in an unconsolidated affiliate		47,588			42,347			96,689			83,677
Loss on extinguishment of debt		-			-			-			92,440
Change in fair value of derivative liabilities		374,195			-			(102,805	)		-
Interest expense – related party		30,835			885			61,358			1,770
Interest expense and prepayment penalties – other		108,966			55,556			203,684			483,656
Total other income (expense)		(561,584	)		(98,788	)		(258,926	)		(661,543	)

Loss from continuing operations:	$	(1,623,433	)	$	(1,560,669	)	$	(2,134,956	)	$	(3,405,047	)

Discontinued operations:
Loss from discontinued operations		2,400			(73	)		2,400			3,125
Gain on disposal of subsidiary		-			-			-			(1,163,609	)
Income gain from discontinued operations:	$	(2,400	)	$	73		$	(2,400	)	$	1,160,484

Net loss:		(1,625,833	)		(1,560,596	)		(2,137,356	)		(2,244,563	)
Net gain attributable to non-controlling interest:		-			(109,226	)		-			(107,462	)
Net loss attributable to Company:	$	(1,625,833	)	$	(1,451,370	)	$	(2,137,356	)	$	(2,137,101	)

Basic and diluted net loss per share:
Continuing operations	$	(0.02	)	$	(0.03	)	$	(0.03	)	$	(0.07	)
Discontinued operations	$	-		$	-		$	-		$	0.02
Net loss per share:	$	(0.02	)	$	(0.03	)	$	(0.03	)	$	(0.05	)

Weighted average common shares outstanding:
Basic and Diluted		72,905,911			52,827,998			72,530,557			48,650,090

See accompanying notes to financial statements

Alliance BioEnergy Plus, Inc.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	Six Months Ended			Six Months Ended
	June 30, 2017			June 30, 2016
Cash flows from operating activities
Net loss from continuing operations		(2,134,956	)		(2,241,438	)
Net income (loss) from discontinued operations		(2,400	)		(3,125	)
Net loss	$	(2,137,356	)	$	(2,244,563	)
Reconciliation of net loss to net cash used in operating activities
Depreciation and amortization		37,738			36,503
Amortization of non-cash compensation		242,217			581,607
Extinguishment of debt		-			92,440
Non-cash interest expense		92,741			68,167
Change in fair value of derivative liabilities		(102,805	)		-
Stock based compensation for services		112,164			160,380
Issuance of warrants for services		81,140			680,265
Issuance of options awarded under employee, director plan		120,097			200,720
Equity loss in an unconsolidated affiliate		96,689			83,677
Changes in operating assets and liabilities
Prepaid expenses		(21,072	)		12,399
Accrued interest - other		37,847			8,097
Accounts payable and accrued liabilities		329,166			123,389
Net cash (used in) operating activities – continuing operations		(1,109,034	)		(193,794	)
Changes in discontinued operations assets and liabilities
Gain on disposal of subsidiary		-			(1,163,609	)
Net cash (used in) operating activities – discontinued operations		(2,400	)		(1,166,734	)
Net cash (used in) operating activities		(1,111,434	)		(1,360,528	)

Cash flows from investing activities
Purchase of property and equipment		(8,000	)		(18,037	)
Security deposits		-			971
Capitalized costs		-			(58,476	)
Investment in and advances to an unconsolidated affiliate		(118,627	)		(94,662	)
Net cash (used in) investing activities – continuing operations		(126,627	)		(170,204	)
Net cash (used in) investing activities – discontinued operations		-			-
Net cash (used in) investing activities		(126,627	)		(170,204	)

Cash flows from financing activities
Proceeds from issuance of common stock		672,501			2,216,994
Proceeds from issuance of convertible debt		870,250			500,000
Proceeds from short-term note payable – related party		20,000			-
Repayment of short-term note payable – related party		(20,000	)		-
Repayment of convertible debt		-			(884,000	)
Repayment of short-term note payable – other		-			(265,000	)
Disgorgement of short-swing stock profits		-			6,526
Net cash provided by financing activities – continuing operations		1,542,751			1,574,520
Net cash provided by financing activities – discontinued operations		-			-
Net cash provided by financing activities		1,542,751			1,574,520

Net (decrease) in cash and cash equivalents		304,690			43,788

Cash and cash equivalent at beginning of the period		49,680			62,054
Cash and cash equivalent at end of the period	$	354,370		$	105,842

Supplemental disclosure of cash flow information
Cash paid during the period for
Interest	$	-		$	512,046
Taxes		-			-

Supplemental schedule of non-cash activities
Conversion of convertible debenture to common stock	$	-		$	333,301
Common stock issued for future services		270,001			290,920
Warrants issued for future services		51,354			741,790
Rescinded common stock issued under the employee, director plan		500			-
Cashless conversion of warrants		501,195			-

See accompanying notes to financial statements

ALLIANCE BIOENERGY PLUS, INC.

NOTES TO FINANCIAL STATEMENTS

June 30, 2017

NOTE 1 – ORGANIZATION AND BUSINESS DESCRIPTION

Alliance Bioenergy Plus, Inc (the “Company”) is a technology company focused on emerging technologies in the renewable energy, biofuels and new technologies sectors. From inception through December 5, 2014, the Company was known as Alliance Media Group Holdings, Inc. At inception (March 28, 2012), the Company was organized as a vehicle to engage in the commercial production, distribution and exploitation of Motion Pictures and other Entertainment products. However, in December 2013, a wholly owned subsidiary of the Company, AMG Renewables, LLC (“AMG Renewables”), acquired the controlling interest (51%) in AMG Energy Group, LLC (“AMG Energy”), which owns a fifty percent (50%) interest of Carbolosic, LLC (“Carbolosic”), which holds an exclusive worldwide license to the University of Central Florida’s patented technology (U.S. Patent 8,062,428) known as “CTS™”. The CTS technology is a mechanical/chemical, dry process for converting cellulose material into sugar for use in the biofuels industry as well as other fine chemical manufacturing. The Company’s goal in acquiring the interest in AMG Energy was to develop the CTS technology to a commercial scale and then seek to license the technology to prospective licensees. In September 2014, the Company determined to focus all of the Company’s resources and personnel on the Company’s renewable energy holdings and future energy technologies and to divest the Company of its entertainment-related assets and subsidiaries. The Company therefore determined at that time to divest and sell off, close down or discontinue the operations of its entertainment-related subsidiaries. Effective December 5, 2014, amended the Company’s Articles of Incorporation to change the name of the Company to Alliance Bioenergy Plus, Inc., which is more appropriately descriptive of the new business direction of the Company.

Commencing in March 2016, the Company commenced action to restructure its energy-related holdings through the following transactions;

1) In March 2016, AMG Renewables, a wholly owned subsidiary of the Company, sold its interest in Carbolosic Plant 1 to Carbolosic Energy 1, LLLP, an unrelated third party, in exchange for satisfaction of the outstanding $1,250,000 loan and $36,488 interest between Carbolosic Plant 1 and Carbolosic Energy 1, LLLP. In connection with the transaction, an amount which the Company had prepaid to Carbolosic Energy 1, LLLP ($122,879) for future marketing and interest was eliminated in the sale.

2) In July 2016, the Company determined to restructure its energy holdings under a single wholly owned subsidiary (AMG Energy) such that AMG Energy would own (i) the Company’s fifty percent (50%) interest of Carbolosic (which includes certain licensing rights in North America and Africa) and (ii) the Company’s 100% interest in EK Laboratories, Inc. At the same time, the Company’s interest in Carbolosic Plant 1 was divested. This restructuring was completed on September 19, 2016 when AMG Renewables merged into AMG Energy. Previously, the Company had completed transactions with certain related parties to acquire the remaining 49% of AMG Energy which was not owned by the Company in exchange for an aggregate of 10,240,094 shares of Company common stock and a restructuring of the balance due under a cash payable to the minority AMG Energy Shareholders.

Plan of Operation

The Company is now focused on the development and commercialization of the licensed technology it controls through its affiliate Carbolosic, LLC. Through its wholly owned subsidiary, AMG Energy, the Company owns Ek Laboratories, Inc. and a 50% interest in Carbolosic (which includes certain licensing rights in North America and Africa). The Company has a strategy that includes mergers and acquisitions of existing businesses in the renewable energy and sustainable products industries as well as sub-licensing its patented technologies that it controls through a master license with the University of Central Florida under affiliate Carbolosic and start-up activities which are focused on development of an increasing revenue stream, secure market share and enhancement of shareholder value.

NOTE 2 – GOING CONCERN

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company as a going concern, which assumes the Company will realize its assets and discharge its liabilities in the normal course of business. The Company has not generated any revenue, has incurred losses since inception, has a working capital deficiency of $3,267,751 and may be unable to raise further equity. At June 30, 2017, the Company had incurred accumulated losses of $27,959,871, of which approximately $19,057,087 is non-cash, since its inception. The Company expects to incur significant additional liabilities in connection with its start-up activities. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. These financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty. There are no assurances that the Company will continue as a going concern.

Management believes that the Company’s future success is dependent upon its ability to achieve profitable operations, generate cash from operating activities and obtain additional financing. There is no assurance that the Company will be able to generate sufficient cash from operations, sell additional shares of stock or borrow additional funds. The Company’s inability to obtain additional cash could have a material adverse effect on its financial position, results of operations, and its ability to continue in existence. These financial statements do not include any adjustments that might result from the outcome of this uncertainty

The Company intends to raise additional capital, sell licenses to its CTS technology and continue constructing its full-scale demonstration facility which, once operational, is expected to generate cash flow in amounts sufficient to cover the Company’s operating expenses and debt service.

Through its private offerings, the Company raised $6,809,394 from inception through December 31, 2016 and an additional $672,501 in the six months ended June 30, 2017.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control. Intercompany transactions and balances were eliminated in consolidation.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. The Company’s proportionate share of net income or loss of the entity is recorded in the Consolidated Statements of Operations.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates presented and reported amounts of revenues and expenses during the reporting periods presented. Significant estimates inherent in the preparation of the accompanying Consolidated Financial Statements include estimates of impairment assessment of identifiable intangible assets and valuation allowance for deferred tax assets. Estimates are based on past experience and other considerations reasonable under the circumstances. Actual results may differ from these estimates.

Cash and Cash Equivalents

All highly liquid investments with maturities of three months or less at the date of purchase are considered to be cash equivalents.

Stock Compensation

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance.

Stock-based Compensation Valuation Methodology

Stock-based compensation resulting from the issuance of common stock is calculated by reference to the valuation of the stock on the date of issuance, the expense being recognized as the compensation is earned. Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The fair value of the stock options or warrants granted is estimated at the grant date, using the Black-Scholes option-pricing model, and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option-pricing model on the basis of the fair value of the underlying common stock on the measurement date, adjusted for the unique characteristics of those equity instruments, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing closing market price. Expected volatility was based on the historical volatility of the Company’s closing day market price per share. The expected term of options and warrants was based upon the life of the option, and the risk-free rate used was based on the U.S. Treasury Daily Yield Curve Rate.

The stock compensation issued for services during the six months ended June 30, 2017, was valued on the date of issuance. The following assumptions were used in calculations of the Black-Scholes option pricing models for warrant-based stock compensation issued in the six months ended June 30, 2017:

	01/01/17			02/18/17			03/31/17			04/01/17			05/03/17			06/02/17
Risk-free interest rate		1.93	%		1.92	%		1.93	%		1.93	%		1.86	%		1.71	%
Expected life		5 years			5 years			5 years			5 years			5 years			5 years
Expected dividends		0	%		0	%		0	%		0	%		0	%		0	%
Expected volatility		140.36	%		138.54	%		137.11	%		137.11	%		137.74	%		136.48	%
ALLM common stock fair value	$	0.20		$	0.16		$	0.11		$	0.11		$	0.14		$	0.17

Accounting and Reporting of Discontinued Operations

As required by the FASB ASC Subtopic 205.20, per ASU 2014-08, Discontinued Operations, a component of an entity or a group of components of an entity, or a business or nonprofit activity can be classified as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when any of the following occurs: (i) the criteria in paragraph 205.20.45.1E to be classified as held for sale is met (ii) the component is disposed of by sale, or (iii) the component is disposed of other than by sale in accordance with paragraph 360.10.45.15 (for example, by abandonment or in a distribution to owners in a spinoff). Certain components to be disposed of other than by sale shall continue to be classified as “held and used” until it is disposed of, per the requirements of ASC Subtopic 360.10. Depreciation on these assets ceases upon their classification as “held and used.” The Company adopted ASU No. 2014-08 effective September 1, 2014.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. Depreciation is provided for on a straight-line basis over the useful lives of the assets, generally 5 to 7 years. Expenditures for additions and improvements are capitalized; repairs and maintenance are expensed as incurred.

Convertible Instruments

The Company evaluates and account for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company accounts for convertible instruments (when we have determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

Accounting for Derivative Instruments

The Company issues debentures where the number of shares into which a debenture can be converted is not fixed. For example, when a debenture converts at a discount to market based on the stock price on the date of conversion. In such instances, the embedded conversion option of the convertible debentures is bifurcated from the host contract and recorded at their fair value. In accounting for derivatives, the Company records a liability representing the estimated present value of the conversion feature considering the historic volatility of the Company’s stock, and a discount representing the imputed interest associated with the beneficial conversion feature. The discount is then amortized over the life of the debenture and the derivative liability is adjusted periodically according to stock price fluctuations. At the time of conversion, any remaining derivative liability is charged to additional paid-in capital. For purposes of determining derivative liability, the Company uses Black-Scholes modeling for computing historic volatility.

Common Stock Purchase Warrants and Other Derivative Financial Instruments

The Company classifies as equity any contracts that require physical settlement or net-share settlement or provide it with a choice of net-cash settlement or settlement in the Company’s own shares (physical settlement or net-share settlement) provided that such contracts are indexed to its own stock as defined in ASC 815-40 (“Contracts in Entity’s Own Equity”). The Company classifies as assets or liabilities any contracts that require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the Company’s control) or give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement). The Company assesses the classification of its common stock purchase warrants and other free-standing derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.

Non-controlling interest in consolidated subsidiaries

The accompanying consolidated financial statements include the accounts of Alliance BioEnergy Plus, Inc. and those subsidiaries that the Company has the ability to control either through voting rights or means other than voting rights. For these subsidiaries, the Company records 100% of the revenues, expenses, cash flows, assets and liabilities in its consolidated financial statements. For subsidiaries that the Company controls but hold less than 100% ownership, a non-controlling interest is recorded in the consolidated income statement to reflect the non-controlling interest’s share of the net income (loss), and a non-controlling interest is recorded in the consolidated balance sheet to reflect the non-controlling interest’s share of the net assets of the subsidiary.

Investments in non-consolidated affiliates

Investments in non-consolidated affiliates are accounted for using the equity method or cost basis depending upon the level of ownership and/or the Company’s ability to exercise significant influence over the operating and financial policies of the investee. When the equity method is used, investments are recorded at original cost and adjusted periodically to recognize the Company’s proportionate share of the investees’ net income or losses after the date of investment. When net losses from an investment are accounted for under the equity method exceed its carrying amount, the investment balance is reduced to zero and additional losses are not provided for. The Company resumes accounting for the investment under the equity method if the entity subsequently reports net income and the Company’s share of that net income exceeds the share of net losses not recognized during the period the equity method was suspended. Investments are written down only when there is clear evidence that a decline in value that is other than temporary has occurred.

The Company’s investment in Carbolosic, LLC is accounted for using the equity method of accounting. The Company monitors its investment for impairment at least annually and make appropriate reductions in the carrying value if it determines that an impairment charge is required based on qualitative and quantitative information.

Impairment of Long Lived Assets

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable, the Company compares the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.

Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all of the deferred tax assets will not be realized.

ASC Topic 740.10.30 clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740.10.40 provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. The Company has no material uncertain tax positions for any of the reporting periods presented.

Profit (Loss) per Common Share:

Basic profit (loss) per share amounts have been calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share has been calculated using the weighted-average number of common shares plus the potentially dilutive effect of securities such as outstanding options and warrants. The computation of potential common shares has been performed using the treasury stock method. The warrants and options are antidilutive for all periods presented. When net loss is reported, diluted and basic net loss per share amounts are the same as the impact of potential common shares is antidilutive.

Fair Value Measurements

The Company adopted the provisions of ASC Topic 820, “Fair Value Measurements and Disclosures”, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, payables to related parties, and accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs:

	December 31, 2016			June 30, 2017
Annual dividend yield		-			-
Expected life (years)		4.30			3.80
Risk-free interest rate		1.93	%		1.55	%
Expected volatility		24% - 163	%		23% - 159	%

Fair Value Measurements at

December 31, 2016

Using Fair Value Hierarchy

Level 1

Level 2

Level 3

Liabilities

Embedded derivative liabilities – (Warrant)

794,000

Embedded derivative liabilities – (Debenture)

120,000

Total

914,000

Fair Value Measurements at

June 30, 2017

Using Fair Value Hierarchy

Level 1

Level 2

Level 3

Liabilities

Embedded derivative liabilities – (Warrant)

Embedded derivative liabilities – (Debenture)

310,000

Total

310,000

For the six months ended June 30, 2017, the Company recognized a gain of $102,805 on the change in fair value of its derivative liabilities. At June 30, 2017, the Company did not identify any other assets or liabilities that are required to be presented on the balance sheet at fair value in accordance with ASC 825-10.

Recent Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future either will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations, and cash flows when implemented.

NOTE 4 – INVESTMENT IN UNCONSOLIDATED AFFILIATE

On December 26, 2013, AMG Renewables, LLC, a Florida limited liability company (“AMG Renewables”), a wholly-owned subsidiary of the Company, acquired the controlling interest (51%) in AMG Energy Group, LLC a Florida limited liability company (“AMG Energy”) from certain related parties and subsequently acquired the remaining 49% in 2016. AMG Energy owns a fifty percent (50%) interest of Carbolosic, LLC, a Delaware limited liability company (“Carbolosic”), which holds an exclusive worldwide license to the University of Central Florida’s patented technology (U.S. Patent 8,062,428) known as “CTS™”. The CTS technology is a mechanical/chemical, dry process for converting cellulose material into sugar for use in the biofuels industry as well as other fine chemical manufacturing. The results of AMG Renewables and AMG Energy are consolidated in the Company’s financial statements. AMG Energy’s investment in Carbolosic is accounted for using the equity method of accounting.

The following is a condensed balance sheet of the unconsolidated affiliate as of June 30, 2017 and December 31, 2016 and a comparative statement of operations for the three and six months ending June 30, 2017 and 2016.

Condensed Balance Sheet of Non-Consolidated Affiliates

	June 30, 2017			December 31, 2016
ASSETS
Current Assets
Cash and cash equivalents	$	25		$	199
Total Current Assets		25			199
Other Assets
Prepaid Expenses		17,500			-
Total Other Assets		17,500			-
TOTAL ASSETS	$	17,525		$	199

LIABILITIES AND STOCKHOLDERS EQUITY
Current Liabilities
Accounts payable and accrued liabilities	$	496,160		$	406,475
Interest payable		43,320			31,309
Current notes payable		766,593			657,585
TOTAL CURRENT LIABILITIES		1,306,073			1,095,369

STOCKHOLDERS EQUITY
Accumulated deficit		(1,288,548	)		(1,095,170	)
TOTAL EQUITY		(1,288,548	)		(1,095,170	)

TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	$	17,525		$	199

Condensed Statement of Operations of Non-Consolidated Affiliates

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2017			2016			2017			2016

Revenues	$	-		$	-		$	-		$	-

Operating Expenses
Royalties		17,500			17,500			35,000			35,000
General and administrative		71,372			62,554			146,367			121,263
Total operating expenses		(88,872	)		(80,054	)		(181,367	)		(156,263	)

Other expenses
Interest expense		6,305			4,640			12,011			8,603
Total other expenses		(6,305	)		(4,640	)		(12,011	)		(8,603	)

Loss from operations	$	(95,177	)	$	(84,694	)	$	(193,378	)	$	(164,866	)

NOTE 5 – DEBT

Short Term Notes Payable - Related Parties

Throughout 2013, the Company issued unsecured short-term notes payable to various related parties, including officers and directors of the Company, with a term of one year, which have since been extended and are coming due June 1, 2018. As of June 30, 2017, there was one consolidated note outstanding to Palm Beach Energy Solutions, LLC. The note has an outstanding principal balance of $71,000 and bears interest at a rate of 5% per annum. As of June 30, 2017 and December 31, 2016, the total interest accrued on the note was $14,356 and $12,596 respectively.

In July 2016, the Company issued six (6) short-term notes payable to related parties in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. These notes have a value of $2,002,126 and accrue interest at a rate of six percent (6%) per annum. As of June 30, 2017 and December 31, 2016, the total interest accrued on the notes was $115,903 and $56,333 respectively. All of the notes are coming due on August 4, 2017 and will be extended until the earlier of an additional 12 months or the company records revenue.

In January 2017, the Company secured a $20,000 short-term bridge loan from a shareholder of the Company. This note did not bear interest and was repaid in February 2017.

Short Term Notes Payable – Other

In July 2016, the Company issued a short-term note payable to a third party in conjunction with the Company’s acquisition of the remaining 49% of AMG Energy Group. The note has a principal balance of $96,570 and accrues interest at a rate of six percent (6%) per annum. As of June 30, 2017 and December 31, 2016, the total interest accrued on the note was $5,667 and $2,794 respectively. The note is coming due on August 4, 2017.

Convertible Debt

On April 25, 2016, the Company entered into a 12-month convertible debenture with JMJ Financial with a principal balance of $555,556. The note carries a 10% one-time interest charge, a 10% original issue discount and a 75% warrant coverage of the amount funded, totaling an aggregate value of $416,666 [$555,556 x 75% = $416,666]. The note may only be paid up to 98% of the balance due within the first 180 days at a 30% premium. After 180 days, the note cannot be repaid without the holders consent. The note is convertible after 180 days at a 25% discount to the lowest trade price in the preceding 10 trading days. Per the warrant coverage feature, the Company issued the investor 1,388,886 warrants with a 5-year term and a cashless exercise price equal to the lesser of $0.30 per share or the lowest trade price in the 10 preceding trading days. The warrant agreement also contains a down-round ratchet provision allowing the holder to increase its warrant count. The number of warrants to issue is calculated by dividing the aggregate value by the lower of $0.30 or the lowest trade price in the 10 preceding trading days. As of March 31, 2017, JMJ Financial has converted $393,892 at $0.135825 per share into 2,900,000 shares of common stock. In addition, JMJ Financial has exercised its warrant agreement ratchet rights, resulting in 3,067,668 [$416,666 / $0.135825 = 3,067,668] warrants outstanding. As of June 30, 2017, the holder had exercised warrants to purchase 11,043 of Company common stock and exercised its cashless conversion feature on the remaining warrants resulting in 1,340,201 shares of common stock issued. As of June 30, 2017 and December 31, 2016, these agreements were valued at $0 and $580,000 along with a total derivative liability of $310,000 and $334,000 respectively. This note is currently in default and is accruing compounding quarterly interest at a rate of eighteen percent (18%) per annum.

In January 2017, the Company entered into a convertible debenture with Power Up Lending Group, Ltd. with a principal balance of $153,500 due and payable on or before October 29, 2017. The note carries an original issue discount of $3,500 and accrues interest at a rate of twelve percent (12%) per annum and is convertible into the Company’s common stock at a 39% discount on the average of the lowest three trading prices during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting every 30 days to a maximum of one hundred thirty percent (130%) of the then outstanding principal and interest balance due, if the note is paid back within the first one hundred eighty (180) days.

In February 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $165,000 due and payable on October 2, 2017. The note carries an 8% one-time interest charge, a $15,000 original issue discount and a 35% conversion discount to the lowest trade price in the prior twenty-five trading days, after 180 days, in whole or in part at the option of the holder. In addition, the Company provided 150,000 inducement shares to secure the note, and may have to provide additional shares on the note’s 6-month anniversary if the Company’s share price declines. These inducement shares were valued at $27,000 and are being amortized over the life of the note. The note can be repaid, without prepayment penalties, within the first 90 days. Thereafter, the note will incur a one hundred twenty percent (120%) prepayment penalty of the then outstanding principal and interest due.

In February 2017, the Company entered into a convertible debenture with Labry’s Fund LLP, with a principal balance of $140,000 due and payable on August 18, 2017. The note carries an original issue discount of $23,000 and accrues interest at a rate of twelve percent (12%) per annum and is convertible into the Company’s common stock at a 50% discount to the lowest trade price during the previous thirty trading days prior to the date of the note or prior to date of conversion, after 180 days, in whole or in part at the option of the holder. The note can be repaid, without prepayment penalties, within the first 180 days. In addition, the Company provided a warrant agreement to purchase up to 250,000 shares of common stock, with a term of 5 years and an exercise price of $0.35 per share of common stock. Using a Black-Scholes option-pricing model, this agreement was valued at $33,265 and is being amortized over the life of the agreement.

In April 2017, the Company entered into a convertible debenture with Auctus Fund, LLC with a principal balance of $117,750 due and payable on or before December 22, 2017. The note carries an original issue discount of $17,750, accrues interest at a rate of twelve percent (12%) per annum and is convertible into the Company’s common stock at a 50% discount on the lowest trading price during the twenty-five trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting after 90 days to a maximum of one hundred thirty-five percent (135%) of the then outstanding principal and interest balance due, if the note is paid back within the first one hundred eighty (180) days.

In April 2017, the Company entered into a convertible debenture with EMA Financial, LLC with a principal balance of $150,000 due and payable on or before March 15, 2018. The note carries an original issue discount of $28,000, accrues interest at a rate of ten percent (10%) per annum and is convertible into the Company’s common stock at a 35% discount on the lowest trading price during the fifteen trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting after 90 days to a maximum of one hundred thirty percent (130%) of the then outstanding principal and interest balance due, if the note is paid back within the first one hundred eighty (180) days.

In May 2017, the Company entered into a convertible debenture with Crown Bridge Partners, LLC with a principal balance of $58,000 due and payable on or before May 4, 2018. The note carries an original issue discount of $9,500, accrues interest at a rate of ten percent (10%) per annum and is convertible into the Company’s common stock at a 40% discount on the lowest trading price during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting every 30 days to a maximum of one hundred thirty-five percent (135%) of the then outstanding principal and interest balance due, if the note is paid back within the first one hundred eighty (180) days.

In May 2017, the Company entered into a convertible debenture with GS Capital Partners Partners, LLC with a principal balance of $115,000 due and payable on or before May 9, 2018. The note carries an original issue discount of $5,750, accrues interest at a rate of eight percent (8%) per annum and is convertible into the Company’s common stock at a 28% discount on the lowest trading price during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting after 90 days to a maximum of one hundred twenty-five percent (125%) of the then outstanding principal and interest balance due, if the note is paid back within the first one hundred eighty (180) days.

In June 2017, the Company entered into a convertible debenture with Power Up Lending Group, Ltd with a principal balance of $53,000 due and payable on or before March 20, 2018. The note carries an original issue discount of $3,000, accrues interest at a rate of eight percent (8%) per annum and is convertible into the Company’s common stock at a 39% discount on the average lowest three day trading price during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting after 60 days to a maximum of one hundred thirty percent (130%) of the then outstanding principal and interest balance due, if the note is paid back within the first one hundred eighty (180) days.

Derivative Liabilities

The embedded conversion features of the above convertible notes payable and warrants contain discounted conversion prices and should be recognized as derivative instruments. Such embedded conversion features should be bifurcated and accounted for at fair value. As of the six months ended June 30, 2017 and the year ended December 31, 2016, the Company had a derivative liability balance of $310,000 and $914,000, respectively. The Company uses the Black-Scholes option-pricing model to calculate derivate liability.

Fair Value of Embedded Derivative Liabilities:

December 31, 2015	$	-
Addition		1,275,547
Converted		(494,721	)
Change in Fair Market Value		7,313
As of December 31, 2016	$	914,000
Addition		-
Converted		(501,195	)
Changes in fair value of derivative liabilities		(102,805	)
As of June 30, 2017	$	310,000

NOTE 6 – STOCKHOLDERS’ EQUITY

The total number of shares of capital stock, which the Company has authority to issue, is five hundred ten million (510,000,000), five hundred million (500,000,000) of which are designated as common stock at $0.001 par value (the “Common Stock”) and ten million (10,000,000) of which are designated as preferred stock par value $0.001 (the “Preferred Stock”). As of June 30, 2017, the Company had 77,284,049 shares of Common Stock issued and outstanding and no shares of Preferred Stock were issued. Holders of shares of Common stock shall be entitled to cast one vote for each share held at all stockholders’ meetings for all purposes, including the election of directors. The Common Stock does not have cumulative voting rights. No holder of shares of stock of any class shall be entitled as a matter of right to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock of any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. The Company has yet to designate any rights, preferences and privileges for any of its authorized Preferred Stock.

In April 2016, the Company entered into a 12-month convertible debenture with JMJ Financial. To obtain the note, the Company issued the holder 1,388,886 warrants with a 5-year term and a cashless exercise price equal to the lesser of $0.30 per share or the lowest trade price in the 10 preceding trading days. In the year ending December 31, 2016, JMJ Financial exercised its warrant agreement ratchet rights, thus rescinding 1,388,886 warrants and reissuing 3,067,668 warrants. SEE NOTE 5. There have been no ratchet right adjustments during the six months ended June 30, 2017. As of June 30, 2017 and December 31, 2016, the holder had exercised all 3,056,625 and 11,043 warrants to acquire 1,340,201 and 11,043 shares of Company common stock respectively. JMJ Financial’s warrant agreement has been fully exercised.

In October 2016, the Company commenced a new offering of units valued at $0.20 per share. Each unit consist of one (1) share of common stock and one (1) five-year Series E warrant convertible to one (1) common share at an exercise price of $0.45. As of June 30, 2017 and December 31, 2016, the Company has sold 3,012,500 and 2,200,050 units for aggregate proceeds of $672,500 and $390,010 respectively. The offering is ongoing.

In the six months ended June 30, 2017, the Company issued an aggregate of 1,723,855 shares of its common stock for services valued at $382,165.

In the six months ended June 30, 2017, the Company issued an aggregate of 950,000 warrants for services. Using a Black-Scholes asset-pricing model, these warrants were valued at $132,494. These warrant agreements have terms of five years (5) with exercise prices ranging from thirty-five cents ($0.35) to two dollars ($2.00) per share.

In the six months ended June 30, 2017, the Company issued options under its Employee & Directors Stock Option Plan to purchase an aggregate of 1,002,876 shares of common stock for a period of five (5) years at average exercise price of $0.13. Using a Black-Scholes asset-pricing model, these agreements were valued at $120,097. In addition, the Company rescinded 500,000 shares of common stock issued to a former employee under the Employee, Director Plan.

NOTE 7 – SEGMENT INFORMATION

The company operates in one segment and does not have any revenue to date.

NOTE 8 - COMMITMENTS AND CONTINGENCIES

Lease

The Company has leased office space pursuant to a lease for a period of thirty-six (36) months from August 5, 2015 through July 31, 2018. Annual rent commenced at approximately $48,925 per annum and increases on a year-to-year basis by three percent (3%) over the Base Year. In addition, the Company is obligated to pay an amount equal to 3.76% of the operating expenses of the building together with sales tax on all amounts.

EK Laboratories leases office and warehouse space in Longwood, FL, which serves as the Company’s research and demonstration facility. The lease period is for thirty-six (36) months from February 1, 2015 through January 31, 2018. Annual rent commences at approximately $70,620 per annum and increases on a year-to-year basis by five percent (5%) over the prior year. The Company also has the right to purchase the property during the lease term.

Rent expense for the three months ended June 30, 2017 and June 30, 2016 were $32,091 and $31,515 respectively, while the rent expense for the six months ended June 30, 2017 and June 30, 2016 were $$64,162 and $63,012 respectively.

NOTE 9 – RELATED PARTY TRANSACTIONS

Related Transactions

Aside from the short-term notes payable issued to related parties that are described in NOTE 5, there have been no related party transaction in the six months ended June 30, 2017.

The officers and directors for the Company are involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interest. The Company has not formulated a policy for the resolution of such conflicts.

NOTE 10 – DISCONTINUED OPERATIONS

On September 1, 2014, the Company determined the need to focus its resources and personnel on the Company’s renewable energy holdings and future energy technologies and to divest the company of its entertainment-related assets and subsidiaries. The principal reasons for such action is the expense, liability and losses that have been generated by the entertainment-related assets and to provide a clear focus and direction to the Company moving forward. Specifically, the Board approved the divesting, selling off, closing down or discontinuing of the operations of its entertainment-related subsidiaries, including but not limited to Prelude Pictures Entertainment, LLC, AMG Live, LLC, AMG Restaurant Operations, LLC (including The New York Sandwich Co.), AMG Music, LLC, AMG Releasing, LLC and AMG Television, LLC.

In March 2016, AMG Renewables, a wholly owned subsidiary of the Company, sold its interest in Carbolosic Plant 1 to Carbolosic Energy 1, LLLP, an unrelated third party, in exchange for satisfaction of the outstanding $1,250,000 loan and $36,488 interest between Carbolosic Plant 1 and Carbolosic Energy 1, LLLP. In connection with the transaction, an amount which the Company had prepaid to Carbolosic Energy 1, LLLP ($122,879) for future marketing and interest was eliminated in the sale.

Below is a reconciliation of the total assets and liabilities of the discontinued operations, which are presented separately on the balance sheet.

	June 30, 2017		December 31, 2016

Carrying amounts of major classes of assets included as part of discontinued operations
Prepaid expenses		-		-
Total assets of the discontinued operation	$	-	$	-

Carrying amounts of major classes of liabilities included as part of discontinued operations
Accounts payable and accrued liabilities	$	36,148	$	36,148
Total liabilities of the discontinued operation	$	36,148	$	36,148

Below is a reconciliation of the net loss of the discontinued operations, which are presented separately on the statement of operations.

	Three Months Ended						Six Months Ended
	March 31,						March 31,
	2017			2016			2017			2016
Major line items constituting pretax profit (loss) of discontinued operations
Revenue		-			-			-			-
Selling, general and administrative		(2,400	)		(73	)		(2,400	)		(3,125	)
Debt forgiveness from legal settlement		-			-			-			1,163,609
Gain (Loss) from discontinued operations	$	(2,400	)	$	73		$	(2,400	)	$	1,160,411

NOTE 11 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events through the date the financial statements were available to be issued. Based on this evaluation, the Company has identified the following subsequent events:

Since July 1, 2017, the Company has sold 325,000 units for aggregate proceeds of $65,000.

Since July 1, 2017, the Company has issued 22,177 shares of common stock for services valued at $6,800.

Since July 1, 2017, the Company has issued 10,000 warrants for services valued at $3,458

In July 2017, the Company entered into a convertible debenture with Lucas Hoppel, with a principal balance of $110,000 due and payable on January 15, 2018. The note carries an original issue discount of $10,000, accrues interest at a rate of eight percent (8%) per annum and is convertible into the Company’s common stock at a 35% discount to the lowest trade price during the previous twenty-five trading days prior to the date of conversion, after 180 days, in whole or in part at the option of the holder. The note carries a prepayment penalty, adjusting every ninety days to a maximum of one hundred twenty percent (120%) of the then outstanding principal and interest balance due, if the note is paid back within the first one hundred eighty (180) days.

In July 2017, the Company paid back its January 2017 convertible note with Power Up Lending Group, Ltd. A total payment of $211,293 was issued, representing $153,500 in principal and $57,793 in interest and penalties.

In July 2017, the Company entered into a convertible debenture with Power Up Lending Group, Ltd. with a principal balance of $153,000 due and payable on or before, 2017. The note carries an original issue discount of $3,000 and accrues interest at a rate of eight percent (8%) per annum and is convertible into the Company’s common stock at a 39% discount on the average of the lowest three trading prices during the ten trading days prior to conversion, after 180 days, in whole or in part at the option of the holder. The note also carries a prepayment penalty, adjusting every 30 days to a maximum of one hundred thirty percent (130%) of the then outstanding principal and interest balance due, if the note is paid back within the first one hundred eighty (180) days.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS AND PLAN OF OPERATION

The following discussion should be read in conjunction with our unaudited financial statements and the notes thereto.

Forward-Looking Statements

This quarterly report contains forward-looking statements and information relating to the Company that are based on the beliefs of its management as well as assumptions made by, and information currently available to, its management. When used in this report, the words “believe,” “anticipate,” “expect,” “estimate,” “intend”, “plan” and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. These statements reflect management’s current view of the Company concerning future events and are subject to certain risks, uncertainties and assumptions, including among many others: a general economic downturn; a downturn in the securities markets; federal or state laws or regulations having an adverse effect on proposed transactions that the Company desires to effect; Securities and Exchange Commission regulations which affect trading in the securities of “penny stocks”; and other risks and uncertainties. Should any of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this report as anticipated, estimated or expected. The accompanying information contained in this registration statement, including, without limitation, the information set forth under the heading “Management’s Discussion and Analysis and Plan of Operation — Risk Factors” identifies important additional factors that could materially adversely affect actual results and performance. You are urged to carefully consider these factors. All forward-looking statements attributable to the Company are expressly qualified in their entirety by the foregoing cautionary statement.

Business Overview

Alliance Bioenergy Plus, Inc (the “Company”) is a technology company focused on emerging technologies in the renewable energy, biofuels and new technologies sectors. In December 2013, a wholly owned subsidiary of the Company, AMG Renewables, LLC (“AMG Renewables”), acquired the controlling interest (51%) in AMG Energy Group, LLC (“AMG Energy”) and the remaining 49% was then acquired in 2016. AMG Energy Group owns a fifty percent (50%) interest of Carbolosic, LLC (“Carbolosic”), which holds an exclusive worldwide license to the University of Central Florida’s patented technology (U.S. Patent 8,062,428) known as “CTS™”. The CTS technology is a mechanical/chemical, dry process for converting cellulose material into sugar for use in the biofuels industry as well as other fine chemical manufacturing. The Company’s goal in acquiring the interest in AMG Energy is to develop the CTS technology to a commercial scale and then seek to license the technology to prospective licensees.

Plan of Operation

The Company is focused on the development and commercialization of the licensed technology it controls through its affiliate Carbolosic, LLC. Through its wholly owned subsidiary, AMG Energy, the Company owns Ek Laboratories, Inc. and a 50% interest in Carbolosic (which includes certain licensing rights in North America and Africa). The Company has a strategy that includes mergers and acquisitions of existing businesses in the renewable energy and sustainable products industries as well as sublicensing its patented technologies that it controls through a master license with the University of Central Florida under affiliate Carbolosic and start-up activities which are focused on development of an increasing revenue stream, secure market share and enhancement of shareholder value.

AMG ENERGY GROUP, LLC

AMG Energy, a wholly owned subsidiary of the Company, was created for the purpose of holding, managing and developing the Company’s renewable energy technology enterprises. These interests comprise ownership of 100% of EK Laboratories, Inc., a Florida corporation (“EK”) formerly known as Central Florida Institute of Science and Technology, Inc. and a fifty percent (50%) interest in Carbolosic, LLC, a Delaware limited liability company (“Carbolosic”), which holds an exclusive worldwide license to the University of Central Florida’s patented technology (U.S. Patent 8,062,428) known as “CTS™”. The CTS technology is a mechanical/chemical, dry process for converting cellulose material into sugar for use in the biofuels industry as well as other fine chemical manufacturing. The Company’s goal is to develop this CTS technology to a commercial scale and then seek to acquire existing bioenergy and ethanol plants to install the CTS technology as well as license the technology to prospective licensees. EK was formed to serve as a pilot plant and research facility to further develop the CTS process, its uses, and develop new technologies.

The Company believes that its management and consultants have significant experience in the bio-fuels, renewable energy and chemical manufacturing industries. As of this date, the Company has not generated any revenues from its renewable energy business.

Capital Formation

In October 2016, the Company commenced a new offering of units valued at $0.20 per share. Each unit consist of one (1) share of common stock and one (1) five-year Series E warrant convertible to one (1) common share at an exercise price of $0.45. From January 1, 2017 through the date of filing and at December 31, 2016, the Company has sold 3,337,500 and 2,200,050 units for aggregate proceeds of $737,500 and $390,010 respectively. The offering is ongoing.

From January 1, 2017 through the date of filing, the Company issued an aggregate of 1,746,032 shares of its common stock for services valued at $388,965.

From January 1, 2017 through the date of filing, the Company issued an aggregate of 960,000 warrants for services. Using a Black-Scholes asset-pricing model, these warrants were valued at $135,952. These warrant agreements have terms of five years (5) with exercise prices ranging from thirty-five cents ($0.35) to two dollars ($2.00) per share.

From January 1, 2017 through the date of filing, the Company issued options to its employees and independent directors to purchase an aggregate of 502,876 shares of common stock for a period of five (5) years at average exercise price of $0.13. Using a Black-Scholes asset-pricing model, these agreements were valued at $72,235. In addition, the Company rescinded 500,000 shares of common stock issued to a former employee under the Employee, Director Plan.

From January 1, 2017 through the date of filing, the Company awarded employees of the Company with an aggregate of 6,500,000 options under its Employee, Director Plan. 500,000 options are fully vested and the remaining 6,000,000 options vest over the next five years. These option agreements have a term of five years (5) and an exercise price ranging from thirteen cents ($0.13) to sixteen cents ($0.16) per share. Using a Black-Scholes asset-pricing model, these options were valued at $47,862.

Going Concern

The Company has incurred losses since inception, has a working capital deficiency, and may be unable to raise further equity. At June 30, 2017, the Company had a working capital deficiency of $3,267,751 and had incurred accumulated losses of $27,959,871 of which approximately $19,057,087 is non-cash, since its inception. The Company expects to incur significant additional losses in connection with its continued start-up activities. As a result, the report of the Company’s independent registered public accounting firm on the Company’s financial statements for the period ended December 31, 2016 contains an emphasis of matter paragraph regarding the Company’s ability to continue as a going concern based upon recurring operating losses and its need to obtain additional financing to sustain operations. The Company’s ability to continue as a going concern is dependent upon its ability to obtain the necessary financing to meet its obligations and repay its liabilities when they become due and to generate sufficient revenues from its operations to pay its operating expenses. Furthermore, these financial statements do not include any adjustments related to the recoverability and classifications of recorded asset amounts, or amounts and classifications of liabilities that might result from this uncertainty.

Through its private offerings, the Company raised $3,079,004 for the year ended December 31, 2016 and an additional $672,500 in the six months ended June 30, 2017 and $35,000 from July 1, 2017 through the date of filing.

Results of Operations

Comparison of the three and six month periods ended June 30, 2017 to June 30, 2016

For the three months ended June 30, 2017, the Company’s general and administrative expenses decreased by approximately $400,032 to $1,061,849 from $1,461,881 in the three months ended June 30, 2016. This decrease is primarily the result of a $231,452 decrease in professional fees. Of the $1,061,849 general and administrative expense, approximately 40% or $424,956 is non-cash equity compensation.

During the six months ended June 30, 2017, the Company’s general and administrative expenses decreased by approximately $867,474 to $1,876,030 from $2,743,504 in the six months ended June 30, 2016. This decrease is primarily the result of a $567,721 reduction in professional fees. Of the $1,876,030 general and administrative expense, approximately 40% or $745,957 is non-cash equity compensation.

Interest expense increased in the three months ended June 30, 2017 by approximately $83,360 to $139,801 from $56,441 during the three months ended June 30, 2016. The increase was the result of additional short-term notes acquired in 2017.

During the six months ended June 30, 2017, the Company’s interest expense decreased by approximately $220,384 to $265,042 from $485,426. The decrease was a the result of the early repayment of 7 convertible notes along with prepayment interest during the six months ended June 30, 2016 and no repayments in the six months ending June 30, 2017.

For the three months ended June 30, 2017, the Company’s equity loss in its unconsolidated affiliate increased $5,241 to $47,588 from $42,347 during the three months ended June 30, 2016.

During the six months ended June 30, 2017, the Company’s equity loss in its unconsolidated affiliate increased by $13,012 to $96,689 from $83,677 during the six months ended June 30, 2016.

The Company’s discontinued operations expenses $2,400 for legal fees during the three and six months ended June 30, 2017, compared to a $1,160,484 gain incurred in the six months ended June 301, 2016, which was the result of the Company’s decision to sell its interest in Carbolosic Plant 1.

Research and development (R&D) expenses for the three months ended June 30, 2017 were $7,096 as opposed to $2,897 for the three months ended June 30, 2016. For the six months ended June 30, 2017, the Company expensed $12,845 as opposed to $7,131 expensed during the six months ended June 30, 2016. The increase in R&D expenses is the result of increased sampling and testing of various feedstocks for the Company’s proposed Vero Beach facility as well as potential third party licensees.

Liquidity and Capital Resources

Liquidity

As of June 30, 2017, the Company had $354,370 in cash and total stockholders’ equity was $5,013,001. Total debt from continuing operations, including advances, accounts payable and other notes payable at June 30, 2017, together with interest payable thereon, was $4,351,326 an increase of $710,334 from $3,640,992 at December 31, 2016. This increase is attributable to the addition of approximately $870,250 in convertible debt.

During the six months ended June 30, 2017, the Company’s continuing operating activities used $1,109,034 in cash. This use can be attributed to payroll, professional and legal fees.

During the six months ended June 30, 2017 the Company’s investing activities used $126,627 in cash, which $118,627 was advanced to Carbolosic, LLC for payment of the minimum annual royalty and patent legal fees.

During the six months ended June 30, 2017, the Company generated $1,542,751 through its financing activities. This can primarily be attributed to the addition of an aggregate net amount of $870,250 in convertible debt and simultaneously raising $672,501 through its ongoing offerings.

Capital Resources

At this time, the Company has limited liquidity and capital resources. To continue funding the Company’s operations, the company will need to generate revenue and/or will require additional funding for ongoing operations and to finance such projects it may identify. As of the date of filing, the Company has raised $672,501 in addition to $6,809,394 raised through December 31, 2016 for a total of $7,481,895 through its private placement offerings. However, there is no guarantee that the company will be able to raise any additional capital on terms acceptable to the Company.

The inability to obtain this funding either in the near term and/or longer term will materially affect the ability of the Company to implement its business plan of operations and jeopardize the viability of the Company. In that case, the Company may need to reevaluate and revise its operations.

Critical Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements of the Company were prepared in accordance with generally accepted accounting principles in the U.S. (“U.S. GAAP”) for interim financial information set forth in Regulation S-X and include the assets, liabilities, revenues and expenses of the Company’s majority-owned subsidiaries over which the Company exercises control. Intercompany transactions and balances were eliminated in consolidation. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals considered necessary for a fair presentation, have been included. Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 or any other period. For further information, refer to the financial statements and footnotes thereto for the period ended December 31, 2016.

Principles of Consolidation

The Company’s consolidated financial statements include the accounts of the Company and its subsidiaries, after elimination of intercompany accounts and transactions. Investments in business entities in which the Company lacks control but has the ability to exercise significant influence over operating and financial policies are accounted for using the equity method. The Company’s proportionate share of net income or loss of the entity is recorded in the Consolidated Statements of Earnings.

Use of Estimates

Stock Compensation

The Company recognizes the cost of all share-based payments under the relevant authoritative accounting guidance. Share-based payments include any remuneration paid by the Company in shares of the Company’s common stock or financial instruments that grant the recipient the right to acquire shares of the Company’s common stock. For share-based payments to employees, which consist only of awards made under the stock option plan described below, the Company accounts for the payments in accordance with the provisions of ASC Topic 718, “Stock Compensation” (formerly referred to as SFAS No. 123(R)). Share-based payments to consultants, service providers and other non-employees are accounted for under in accordance with ASC Topic 718, ASC Topic 505, “Equity Payments to Non-Employees” or other applicable authoritative guidance

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815 “Derivatives and Hedging Activities”.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

Accounting for Derivative Instruments

Recent Accounting Pronouncements

In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this Update remove the definition of a development stage entity from the Master Glossary of the Accounting Standards Codification, thereby removing the financial reporting distinction between development stage entities and other reporting entities from GAAP. In addition, the amendments eliminate the requirements for development stage entities to (1) present inception-to-date information in the statements of income, cash flows, and shareholder equity, (2) label the financial statements as those of a development stage entity, (3) disclose a description of the development stage activities in which the entity is engaged, and (4) disclose in the first year in which the entity is no longer in a development stage that in prior years it had been in the development stage.

The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. Finally, the amendments remove paragraph 810-10-15-16. Paragraph 810-10-15-16 states that a development stage entity does not meet the condition in paragraph 810-10-15-14(a) to be a variable interest entity if (1) the entity can demonstrate that the equity invested in the legal entity is sufficient to permit it to finance the activities that it is currently engaged in and (2) the entity’s governing documents and contractual arrangements allow additional equity investments. The amendments in this Update also eliminate an exception provided to development stage entities in Topic 810, Consolidation, for determining whether an entity is a variable interest entity on the basis of the amount of investment equity that is at risk. The amendments to eliminate that exception simplify GAAP by reducing avoidable complexity in existing accounting literature and improve the relevance of information provided to financial statement users by requiring the application of the same consolidation guidance by all reporting entities. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage. The amendments related to the elimination of inception-to-date information and the other remaining disclosure requirements of Topic 915 should be applied retrospectively except for the clarification to Topic 275, which shall be applied prospectively. For public business entities, those amendments are effective for annual reporting periods beginning after December 15, 2014, and interim periods therein. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company adopted ASU No. 2014-10 effective July 31, 2014.

Off-Balance Sheet Arrangements

The Company does not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Seasonality

The Company’s operating results are not affected by seasonality.

Inflation

The Company’s business and operating results are not affected in any material way by inflation.

Contractual Obligations

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide this information.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

ITEM 4. CONTROLS AND PROCEDURES

(a)

Disclosure Controls and Procedures

The Company is required to maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in its reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to the Company’s management, including its chief executive officer (also its principal executive officer) and its chief financial officer (also its principal financial and accounting officer) to allow for timely decisions regarding required disclosure.

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), the Company’s management, including the Company’s President (“President”), the Company’s principal executive officer (“CEO”) and Chief Financial Officer (“CFO”) (the Company’s principal financial and accounting officer), have evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation the Company’s CEO, President and CFO concluded that the Company’s disclosure controls and procedures were not effective as of June 30, 2017 to a reasonable assurance level to enable the Company to record, process, summarize and report information required under the Securities and Exchange Commission’s rules in a timely fashion. This conclusion resulted from the lack of separation of duties within the Company.

(b)

Management’s Report on Internal Control over Financial Reporting

The Company’s management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:

	●	Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;

	●	Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

	●	Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

As of June 30, 2017, management assessed the effectiveness of the Company’s internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013) and SEC guidance on conducting such assessments. Based on that evaluation, the Company concluded that, during the period covered by this report, such internal controls and procedures were not effective to detect the inappropriate application of US GAAP rules as more fully described below. This was due to deficiencies that existed in the design or operation of its internal controls over financial reporting that adversely affected its internal controls and that may be considered to be material weaknesses.

The matters involving internal controls and procedures that the Company’s management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board was (a) the lack of a functioning audit committee, (b) there are insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of US GAAP and SEC disclosure requirements, (c) there is a lack of expertise with US generally accepted accounting principles and SEC rules and regulations for review of critical accounting areas and disclosures and material non-standard transactions and (d) lack of effective oversight during the financial close process resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures. The aforementioned material weaknesses were identified by the Company’s management in connection with the review of its financial statements for the six months ended June 30, 2017.

Management believes that the material weakness set forth above did not have an effect on its financial results. However, management believes that the lack of a functioning audit committee coupled with not having individuals on staff or retainer with a thorough knowledge of US GAAP and SEC rules and regulations and lack of effective oversight on the financial close process results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in its financial statements in future periods.

This quarterly report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by its registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report in this quarterly report.

Remediation Plan

Management is sensitive to the issues presented and intends to take appropriate action when the Company’s financial resources permit. Management intends to hire additional support staff when its financial resources permit and it will continue to review and make necessary changes to the overall design of its internal control environment.

(c)

Reclassification of prior Period Financial Statements

Certain items previously reported have been reclassified to conform with the current period’s presentation.

(d)

Changes in Internal Control over Financial Reporting

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) under the Exchange Act) during the fiscal period to which this report relates that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

The Company is subject, from time to time, to litigation, claims and suits arising in the ordinary course of business. As of the date of filing, there are no material claims or suits whose outcomes could have a material effect on the Company’s financial statements.

ITEM 1A.

RISK FACTORS.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES

Below is a list of securities sold by the Company from January 1, 2017 through the date of filing which were not registered under the Securities Act.

Name of Purchaser

Date of Sale

Title of Security

Amount of Securities Sold

Consideration

Joseph A Galbo

01/01/17

Common Stock

12,500

Professional Services

Luna Consultant Group, LLC

01/27/17

Common Stock

500,000

Professional Services

Major League Services Investment & Holdings Corp.

01/30/17

Common Stock

62,500

Purchased @ $0.20 per share

Gretchen Hickman

01/31/17

Common Stock

25,000

Purchased @ $0.20 per share

Nadia Marrese

01/31/17

Common Stock

25,000

Purchased @ $0.20 per share

Harry Grossman

01/31/17

Common Stock

8,000

Professional Services

Ken Hickman

01/31/17

Common Stock

2,500

Professional Services

Joseph A Galbo

02/01/17

Common Stock

12,500

Professional Services

Lucas Hoppel

02/02/17

Common Stock

150,000

Inducement to secure a debt note

Harry Grossman

02/28/17

Common Stock

8,000

Professional Services

Joseph A Galbo

03/01/17

Common Stock

12,500

Professional Services

David Matthews

03/10/17

Common Stock

(500,000

)

Rescinded Employment Stock

Steven Tureff & Donnis Newman

03/20/17

Common Stock

50,000

Purchased @ $0.20 per share

Ken Hickman

03/20/17

Common Stock

3,571

Professional Services

Harry Grossman

03/31/17

Common Stock

8,000

Professional Services

Joseph A Galbo

04/01/17

Common Stock

12,500

Professional Services

John Cannon

04/17/17

Common Stock

25,000

Purchased @ $0.20 per share

Ken Hickman

04/17/17

Common Stock

1,471

Professional Services

Porter, LeVay & Rose, Inc.

04/17/17

Common Stock

100,000

Professional Services

Minal Patel

04/24/17

Common Stock

50,000

Purchased @ $0.20 per share

Ken Hickman

04/24/17

Common Stock

3,571

Professional Services

Martin Weinstein

04/25/17

Common Stock

50,000

Purchased @ $0.20 per share

Ken Hickman

04/25/17

Common Stock

3,847

Professional Services

Harry Grossman

04/30/17

Common Stock

8,000

Professional Services

Nadia Marrese

05/03/17

Common Stock

25,000

Purchased @ $0.20 per share

Ken Hickman

05/03/17

Common stock

1,786

Professional Services

Edward Peters

05/19/17

Common Stock

50,000

Purchased @ $0.20 per share

Ken Hickman

05/19/17

Common Stock

3,572

Professional Services

Harry Grossman

05/31/17

Common Stock

8,000

Professional Services

AES Capital Partners, LP

06/02/17

Common Stock

100,000

Professional Services

John D. Lane Corporation

06/02/17

Common Stock

250,000

Professional Services

The AES Capital Resource Fund, L.P.

06/14/17

Common Stock

2,500,000

Purchased @ $0.20 per share

Martin Weinstein

06/15/17

Common stock

25,000

Purchased @ $0.20 per share

Ken Hickman

06/15/17

Common Stock

1,250

Professional Services

Nadia Marrese

06/24/17

Common Stock

50,000

Purchased @ $0.20 per share

Bryan White

06/26/17

Common Stock

50,000

Purchased @ $0.20 per share

Michael Geisler

06/26/17

Common Stock

25,000

Purchased @ $0.20 per share

Ken Hickman

06/26/17

Common Stock

4,287

Professional Services

Luna Consultant Group, LLC

06/27/17

Common Stock

500,000

Professional Services

Harry Grossman

06/30/17

Common Stock

8,000

Professional Services

JMJ Financial

06/30/17

Common Stock

1,340,201

Cashless Warrant Exercise

John D. Lane Corporation

07/01/17

Common Stock

10,000

Professional Services

Gretchen Hickman

07/10/17

Common Stock

25,000

Purchased @ $0.20 per share

Bryan White

07/13/17

Common Stock

50,000

Purchased @ $0.20 per share

Donnis Newman

07/13/17

Common Stock

25,000

Purchased @ $0.20 per share

Nadia Marrese

07/13/17

Common Stock

25,000

Purchased @ $0.20 per share

Steven Tureff

07/13/17

Common Stock

25,000

Purchased @ $0.20 per share

Ken Hickman

07/13/17

Common Stock

4,897

Professional Services

Deanna Hern

07/14/17

Common stock

25,000

Purchased @ $0.20 per share

Ken Hickman

07/19/17

Common Stock

758

Professional Services

Camilla Blaffer

07/24/17

Common Stock

150000

Purchased @ $0.20 per share

Ken Hickman

07/24/17

Common Stock

6,522

Professional Services

The securities issued in the above-mentioned transactions were issued in connection with private placements exempt from the registration requirements of Section 5 of the Securities Act of 1933, as amended, pursuant to the terms of Section 4(2) of that Act and Rules 505 and 506 of Regulation D.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

None.

ITEM 6.

EXHIBITS

Exhibit No.		Description

31.1		Certification of Principal Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Principal Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Principal Executive Officer and Principal Financial Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

	ALLIANCE BIOENERGY PLUS, INC.

Date: August 11, 2017	By:	/s/ Daniel de Liege
		Daniel de Liege
		Director, CEO, Acting CFO, President, Secretary and Treasurer
		(Principal Executive Officer)

Date: August 11, 2017	By:	/s/ Daniel de Liege
		Daniel de Liege
		Director, CEO, Acting CFO, President, Secretary and Treasurer
		(Principal Financial and Accounting Officer)

EXHIBIT INDEX

Exhibit No.		Description

31.1		Certification of Principal Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Principal Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Principal Executive Officer and Principal Financial Officer furnished pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

BLUE BIOFUELS, INC. - FORM 10-Q - August 11, 2017

Attached files

BLUE BIOFUELS, INC. Reports